Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe Europe - 06/22 09:00:39 am
1537.4 GBp   -0.07%
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to..
RE
06/20GLAXOSMITHKLINE : Savvy senior
AQ
06/18KRAFT HEINZ : WHAT A HORLICKS Malted milk drink with 145-year histor..
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Australian watchdog takes GlaxoSmithKline, Novartis units to court

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/06/2017 | 12:26am CEST
Swiss drugmaker Novartis' logo is seen in Stein

(Reuters) - The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline (>> GlaxoSmithKline) and Swiss healthcare company Novartis (>> Novartis) to court over false or misleading representations in the marketing of pain relief products.

(Reuters) - The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline (>> GlaxoSmithKline) and Swiss healthcare company Novartis (>> Novartis) to court over false or misleading representations in the marketing of pain relief products.

The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated".

"We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.

ACCC's concerns come as a price sampling conducted by it noted that supermarkets and pharmacies often sold Osteo Gel at a significant price premium to Emulgel.

The regulator is seeking declarations, injunctions, pecuniary penalties, and a publication order in relation to its allegations.

"The alleged conduct is particularly concerning, given the significant penalties handed down by the court against the makers of Nurofen for what we consider to be similar conduct,” Sims said.

In December last year, the Federal court of Australia upheld an appeal by the regulator against Reckitt Benckiser's (>> Reckitt Benckiser) Australian unit for similar charges on its Nurofen Specific Pain products, imposing a A$6 million (£3.40 million) penalty.

(Reporting by Susan Mathew in Bengaluru; Editing by Stephen Coates)

Stocks treated in this article : Novartis, Reckitt Benckiser, GlaxoSmithKline
Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS -0.78% 73.44 Delayed Quote.-10.87%
RECKITT BENCKISER -0.85% 6158 Delayed Quote.-10.23%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
06/21GLAXOSMITHKLINE : Trademark Application for "ZYBAN ADVANTAGE PLAN" Filed
AQ
06/21GLAXOSMITHKLINE : Recent Findings in Breast Cancer Described by Researchers from..
AQ
06/21GLAXOSMITHKLINE : Research Conducted at GlaxoSmithKline plc Has Provided New Inf..
AQ
06/21GLAXOSMITHKLINE : Findings on Herpes Zoster Virus Reported by Researchers at Gla..
AQ
06/21GLAXOSMITHKLINE : TrialScope Selected by Leading Global Pharmaceutical Company t..
AQ
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20GLAXOSMITHKLINE : Savvy senior
AQ
06/18GLAXOSMITHKLINE : Health and Human Services Department (HHS); Food and Drug Admi..
AQ
06/18KRAFT HEINZ : WHAT A HORLICKS Malted milk drink with 145-year history now a £3bn..
AQ
06/16International fund managers turn to financials, tech as trade worries rise
RE
More news
News from SeekingAlpha
06/19NeuroMetrix receives $3.8M milestone payment under its collaboration with GSK.. 
06/18Aptinyx Proposes Final Terms For $80 Million IPO 
06/18Global Stocks Flashing Red Over China Tariff Retaliation (Wall Street Breakfa.. 
06/18WALL STREET BREAKFAST : Trade Headwinds Blow Stronger 
06/18Epizyme Continues To Chug Along Despite FDA Partial Clinical Hold 
Financials ( GBP)
Sales 2018 29 890 M
EBIT 2018 7 970 M
Net income 2018 3 826 M
Debt 2018 19 384 M
Yield 2018 5,20%
P/E ratio 2018 20,61
P/E ratio 2019 16,67
EV / Sales 2018 3,22x
EV / Sales 2019 3,09x
Capitalization 76 873 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 15,6  GBP
Spread / Average Target 1,4%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE17.20%102 028
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625
MERCK AND COMPANY8.90%164 189